Bachra Choufi
Overview
Explore the profile of Bachra Choufi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thepot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prebet T, et al.
Haematologica
. 2016 May;
101(8):918-25.
PMID: 27229713
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to...
12.
Gac A, Azar N, Daguindau E, Cartron G, Fornecker L, Gyan E, et al.
Leuk Lymphoma
. 2016 Feb;
57(5):1149-53.
PMID: 26879408
Bendamustine is used in the treatment of different relapsing or refractory subtypes of lymphoma. Its impact on the yield of peripheral blood stem cells is not well known. Twenty three...
13.
Cherel M, Choufi B, Trauet J, Cracco P, Dessaint J, Yakoub-Agha I, et al.
Eur J Haematol
. 2014 Feb;
92(6):491-6.
PMID: 24520815
In longitudinal clinical studies, receiving a high percentage of allogeneic donor-derived CD4(+) CCR7(+) T cells, which include naïve and central memory subsets have been correlated with increased incidence and severity...
14.
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al.
J Clin Oncol
. 2012 Oct;
31(1):104-10.
PMID: 23109692
Purpose: To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas. Patients And Methods: Patients with histologically confirmed peripheral T-cell lymphoma (PTCL)...
15.
Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, et al.
Haematologica
. 2009 Dec;
95(6):892-9.
PMID: 20015890
Background: There is little published information on the everyday clinical management of myelodysplastic syndromes in real world practice. Design And Methods: We conducted a cross-sectional study of all patients with...
16.
Bay J, Peffault de Latour R, Tournilhac O, Choufi B, Chassagne J
Bull Cancer
. 2006 Jun;
93(5):473-82.
PMID: 16777625
Hematopoietic growth factors are usually administered in autologous and allogeneic stem cell transplantation. RhuG-CSF and rhuEPO are the most frequently used, either for mobilization of peripheral stem cells or after...
17.
Blaise D, Bay J, Faucher C, Michallet M, Boiron J, Choufi B, et al.
Blood
. 2003 Aug;
103(2):435-41.
PMID: 12946991
In this prospective multicenter program, we investigated allogeneic stem cell transplantation (ASCT) from HLA-identical siblings following reduced-intensity conditioning (RIC) regimen for patients with refractory metastatic solid tumors (STs). Fifty-seven patients,...
18.
Mohty M, Bay J, Faucher C, Choufi B, Bilger K, Tournilhac O, et al.
Blood
. 2003 Mar;
102(2):470-6.
PMID: 12649133
Reduced-intensity conditioning (RIC) regimens are increasingly used for allogeneic stem cell transplantation (allo-SCT). RIC has been shown to allow engraftment with minimal early transplantation-related mortality (TRM). However, in the context...